Legend Biotech Corp (LEGN)
45.41
-0.52
(-1.13%)
USD |
NASDAQ |
May 03, 16:00
45.42
0.00 (0.00%)
After-Hours: 20:00
Legend Biotech Enterprise Value: 7.233B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 7.233B |
| May 02, 2024 | 7.328B |
| May 01, 2024 | 6.973B |
| April 30, 2024 | 6.929B |
| April 29, 2024 | 7.184B |
| April 26, 2024 | 7.213B |
| April 25, 2024 | 7.053B |
| April 24, 2024 | 7.190B |
| April 23, 2024 | 7.604B |
| April 22, 2024 | 7.533B |
| April 19, 2024 | 7.375B |
| April 18, 2024 | 7.544B |
| April 17, 2024 | 7.855B |
| April 16, 2024 | 8.090B |
| April 15, 2024 | 8.379B |
| April 12, 2024 | 8.599B |
| April 11, 2024 | 8.980B |
| April 10, 2024 | 9.067B |
| April 09, 2024 | 9.225B |
| April 08, 2024 | 8.941B |
| April 05, 2024 | 8.965B |
| April 04, 2024 | 9.003B |
| April 03, 2024 | 9.229B |
| April 02, 2024 | 9.238B |
| April 01, 2024 | 9.382B |
| Date | Value |
|---|---|
| March 28, 2024 | 9.176B |
| March 27, 2024 | 9.329B |
| March 26, 2024 | 9.141B |
| March 25, 2024 | 9.280B |
| March 22, 2024 | 9.549B |
| March 21, 2024 | 9.567B |
| March 20, 2024 | 9.893B |
| March 19, 2024 | 10.40B |
| March 18, 2024 | 10.73B |
| March 15, 2024 | 10.62B |
| March 14, 2024 | 11.00B |
| March 13, 2024 | 11.34B |
| March 12, 2024 | 10.82B |
| March 11, 2024 | 10.83B |
| March 08, 2024 | 10.48B |
| March 07, 2024 | 10.65B |
| March 06, 2024 | 10.57B |
| March 05, 2024 | 10.55B |
| March 04, 2024 | 10.71B |
| March 01, 2024 | 10.89B |
| February 29, 2024 | 10.83B |
| February 28, 2024 | 11.30B |
| February 27, 2024 | 11.70B |
| February 26, 2024 | 11.16B |
| February 23, 2024 | 11.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.627B
Minimum
Mar 04 2021
12.94B
Maximum
Jun 22 2023
6.808B
Average
6.634B
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 366.66B |
| Bristol-Myers Squibb Co | 135.24B |
| 2seventy bio Inc | 27.25M |
| Exelixis Inc | 5.416B |
| Alnylam Pharmaceuticals Inc | 17.92B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -144.82M |
| Revenue (Quarterly) | 79.46M |
| Total Expenses (Quarterly) | 199.31M |
| EPS Diluted (Quarterly) | -0.80 |
| Gross Profit Margin (Quarterly) | 59.16% |
| Profit Margin (Quarterly) | -182.2% |
| Earnings Yield | -6.47% |
| Normalized Earnings Yield | -5.644 |